Sign In
Buy NVO
$47.41
-0.0100 (-0.0211%)
At Close: Jun 24, 2026
If You'd Invested $1,000 in Novo Nordisk Stock 5 Years Ago, Here's How Much You'd Have Today
10:37am, Wednesday, 15'th May 2024
No prizes for guessing which hugely popular weight loss drug has driven its growth. Determined competition is on the way, but the Danish pharmaceutical star will have defensive advantages.
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
07:23am, Wednesday, 15'th May 2024
Bagsværd, Denmark, 15 May 2024 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated perso
Novo Nordisk Bets Up to $600 Million on Ozempic 2.0. Here's Why the Stock Is a Buy.
06:45am, Wednesday, 15'th May 2024
Novo Nordisk just made a big collaboration commitment with a biotech. This partner is using advanced techniques to develop new medicines.
Novo Nordisk owner buys majority stake in Austrian life science tools company
02:04am, Wednesday, 15'th May 2024
Novo Holdings, the controlling shareholder of Danish obesity drugmaker Novo Nordisk , said on Wednesday it would buy a controlling stake of about 60% in Single Use Support, an Austria-based life scien
No shortage of Wegovy weight-loss drug in Denmark, Novo Nordisk says
01:56am, Wednesday, 15'th May 2024
Novo Nordisk does not expect a shortage of its Wegovy weight-loss drug in Denmark despite an earlier warning by the Danish Medicines Agency of strained supply of two separate doses in the coming weeks
Healthy Returns: One in eight adults have taken Ozempic or other GLP-1s, survey says
02:35pm, Tuesday, 14'th May 2024
A wide swath of Americans are using GLP-1s despite shortages, a survey says. Meanwhile, Google DeepMind's new AI model can predict the structure of molecules.
Novo Nordisk (NVO) Up 3% as Haemophilia Drug Meets Study Goals
11:06am, Tuesday, 14'th May 2024
Novo Nordisk's (NVO) shares rise 3.1% as the company meets co-primary endpoints in a late-stage study evaluating its investigational candidate, Mim8, for the treatment of haemophilia A.
Here's Why Novo Nordisk (NVO) is a Strong Growth Stock
10:46am, Tuesday, 14'th May 2024
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
People on Novo Nordisk's Wegovy maintain weight loss for up to four years, study says
10:12am, Tuesday, 14'th May 2024
The results shed light on the long-term effects of Wegovy, and could boost Novo Nordisk's case to insurers and governments to cover the costly drug.
Cramer's Stop Trading: Novo Nordisk
10:12am, Tuesday, 14'th May 2024
CNBC's Jim Cramer explains why he is keeping an eye on shares of Novo Nordisk.
2 Top Pharma Stocks That Just Keep Getting Better and Better
09:53am, Tuesday, 14'th May 2024
Eli Lilly and Novo Nordisk are competing in treating diabetes and obesity. Both have launched successful products in these two markets.
Biotech Behemoths: 3 Giants Set to Dominate the Health Scene
06:30am, Tuesday, 14'th May 2024
Biotechnology is an interesting place to look if you're looking for growth and are not put off by severe levels of volatility. Undoubtedly, there's a bit of speculative zest regarding some of the smal
Weight loss wonder drug reduces chance of heart attack and stroke by a fifth
02:59am, Tuesday, 14'th May 2024
Weight loss jabs Wegovy, Ozempic, and Rybelsus could lower the risk of heart attacks, strokes, or heart failure in obese individuals, irrespective of their weight loss, according to a recent study.
Wegovy weight loss sustained for four years in trial, Novo Nordisk says
07:55pm, Monday, 13'th May 2024
Patients taking Novo Nordisk's popular Wegovy obesity treatment maintained an average of 10% weight loss after four years on the treatment, the company said on Tuesday.
Bagsværd, Denmark, 13 May 2024 – Novo Nordisk today announced the headline results from the FRONTIER 2 trial, a pivotal phase 3a, 26-week open-label, randomised, controlled, multi-arm trial in 254
